These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

830 related items for PubMed ID: 17355741

  • 1. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G.
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [Abstract] [Full Text] [Related]

  • 2. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N, Sahin A, Gultekin S.
    J Glaucoma; 2008 Mar; 17(1):36-9. PubMed ID: 18303382
    [Abstract] [Full Text] [Related]

  • 3. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC, Konstas AG, Nelson LA, Kruft B.
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
    Aptel F, Cucherat M, Denis P.
    J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
    [Abstract] [Full Text] [Related]

  • 5. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R.
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P.
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [Abstract] [Full Text] [Related]

  • 7. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
    García-Feijoo J, Martínez-de-la-Casa JM, Castillo A, Méndez C, Fernández-Vidal A, García-Sánchez J.
    Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination.
    Centofanti M, Oddone F, Gandolfi S, Hommer A, Boehm A, Tanga L, Sangermani C, Sportelli V, Haustein M, Manni G, Rossetti L.
    Am J Ophthalmol; 2010 Oct; 150(4):575-80. PubMed ID: 20688314
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ, Walt JG.
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M, Boehm A, Viswanathan A, Vorwerk C, Goldblum D.
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [Abstract] [Full Text] [Related]

  • 11. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.
    Orme M, Collins S, Dakin H, Kelly S, Loftus J.
    Curr Med Res Opin; 2010 Mar; 26(3):511-28. PubMed ID: 20014995
    [Abstract] [Full Text] [Related]

  • 12. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P.
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [Abstract] [Full Text] [Related]

  • 13. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB, WuDunn D, Cortes A, Hoop J, Knotts S.
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
    Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G.
    Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
    [Abstract] [Full Text] [Related]

  • 15. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.
    Holmstrom S, Buchholz P, Walt J, Wickstrøm J, Aagren M.
    Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709
    [Abstract] [Full Text] [Related]

  • 16. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
    Law SK, Song BJ, Fang E, Caprioli J.
    Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
    [Abstract] [Full Text] [Related]

  • 17. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
    Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC.
    Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
    [Abstract] [Full Text] [Related]

  • 18. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma.
    Cheng JW, Cai JP, Li Y, Wei RL.
    J Glaucoma; 2009 Dec; 18(9):652-7. PubMed ID: 20010242
    [Abstract] [Full Text] [Related]

  • 19. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma.
    Quaranta L, Pizzolante T, Riva I, Haidich AB, Konstas AG, Stewart WC.
    Br J Ophthalmol; 2008 Sep; 92(9):1227-31. PubMed ID: 18586898
    [Abstract] [Full Text] [Related]

  • 20. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R, Hwang LJ, Grunden JW, Bean GW.
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.